Calfactant
Brand names: Infasurf · Active ingredient: Calfactant
In short: INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation.
What is Calfactant used for?
INFASURF is indicated:
to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS.
for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation.
Calfactant dosage
2.1 Recommended Dosage
The recommended dose of INFASURF is 3 mL/kg body weight at birth administered intratracheally through an endotracheal tube. INFASURF can be administered every 12 hours for a total of up to three doses.
To reduce the risk of RDS in preterm neonates <29 weeks of gestational age at risk for RDS, administer INFASURF within 30 minutes after birth.
2.2 Preparation Instructions
INFASURF does not require reconstitution. Do not dilute or sonicate.
INFASURF does not need to reach room temperature before administration.
Gently swirl or agitate the INFASURF intratracheal suspension vial for redispersion. Do not shake.
Visually inspect the INFASURF intratracheal suspension for discoloration prior to administration. The color of the INFASURF intratracheal suspension should be off-white. Discard the INFASURF vial if the intratracheal suspension is discolored. Visible flecks in the intratracheal suspension and foaming at the surface are normal.
Using a 20-gauge or larger needle and syringe to avoid excessive foaming, withdraw INFASURF from the vial.
Discard unopened INFASURF vials stored at room temperature for more than 24 hours.
Discard unused INFASURF after the initial vial entry.
2.3 Administration Instructions
INFASURF should be administered by healthcare providers who are experienced in the acute care of neonates with RDS who require intubation. Two attendants should be present to facilitate dosing; one to instill the INFASURF, the other to monitor the neonate.
Administer INFASURF intratracheally through an endotracheal tube using the prepared syringe using either of the following two methods. Instill the INFASURF dose through a:
Side-port adapter into the endotracheal tube as two equal aliquots of 1.5 mL/kg each. During and after each aliquot that is instilled, position the neonate with either the right or the left side dependent and maintain ventilation over 20 to 30 breaths for each aliquot, with small bursts timed only during the inspiratory cycles. Between aliquot administration evaluate the respiratory status and reposition to the other side.
5-French feeding catheter inserted into the endotracheal tube as four equal aliquots of 0.75 mL/kg each. During and after each aliquot is instilled, position the neonate in four different positions (i.e., prone, supine, right, and left lateral) to facilitate even distribution of INFASURF. Remove the catheter between each of the instillations and resume mechanical ventilation for 0.5 to 2 minutes.
After INFASURF administration, frequently monitor neonate oxygenation and ventilatory status .
How to take Calfactant — instructions & advice from the label
Inform caregivers of the following risks of INFASURF:
Advise patient’s caregivers of acute changes in oxygenation and/or lung function typically occur when a surfactant-deficient neonate with respiratory distress is given a surfactant, including INFASURF .
Advise patient’s caregivers of temporary adverse reactions, including skin turning blue, heart rate slowing, airway blockage, or reflux of INFASURF into the infant’s breathing tube may occur when INFASURF is administered . If any of these adverse reactions occurs, the healthcare provider will interrupt INFASURF administration and take appropriate measures to alleviate the adverse reactions.
Advise patient’s caregivers that infants treated with INFASURF may have evidence of bleeding into the brain and/or loss of brain tissue . Bleeding into the brain and loss of brain tissue are sometimes seen in preterm infants, including those who do not receive surfactant treatment, since the main risk factor is being born at or before 32 weeks’ gestation. …
Warnings & precautions
Do not take this medicine if: None.
5.1 Acute Changes in Oxygenation and Lung Compliance
The administration of exogenous surfactants, including INFASURF, can rapidly affect oxygenation and lung compliance. Frequently monitor neonates who receive INFASURF so that oxygen and ventilatory support can be modified in response to changes in respiratory status. INFASURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm neonates with RDS who require intubation.
5.2 Administration-Related Adverse Reactions
Administration-related adverse reactions associated with INFASURF use included cyanosis, bradycardia, airway obstruction, and reflux of INFASURF into the endotracheal tube. These adverse reactions occurred more frequently in neonates who received repeat doses of INFASURF at 12-hour intervals than neonates that received colfosceril palmitate, the comparator, in randomized controlled trials (Trials 1 and 3) . If these adverse reactions occur during INFASURF administration, stop INFASURF and institute appropriate measures to alleviate these adverse reactions and resume INFASURF with appropriate monitoring.
5.3 Intraventricular Hemorrhage and Periventricular Leukomalacia
An increased proportion of INFASURF-treated neonates compared to colfosceril palmitate-treated neonates in randomized clinical trials (Trials 1 and 3) developed intraventricular hemorrhage and periventricular leukomalacia. These adverse reactions were not associated with increased mortality in those studies. In contrast, the same proportion of INFASURF-treated neonates compared to beractant-treated neonates in randomized clinical trials (Trials 2) developed intraventricular hemorrhage and periventricular leukomalacia . …
Calfactant side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Acute Changes in Oxygenation and Lung Compliance
Administration-Related Adverse Reactions
Intraventricular Hemorrhage and Periventricular Leukomalacia
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of INFASURF is based on the pooled safety population from three, randomized, active-controlled clinical trials that evaluated INFASURF to reduce the risk of respiratory distress syndrome (RDS) and rescue treatment of RDS , which included 1,554 preterm neonates who received at least one dose of INFASURF.
The most common INFASURF administration-related adverse reactions were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%).
6.2 Complications of RDS and Neurodevelopmental Outcomes
Incidence of Common Complications of Prematurity
The controlled trials of INFASURF included the incidence of common complications of prematurity and RDS as safety endpoints. Tables 1 and 2 display the results in the INFASURF vs. colfosceril palmitate trials and the INFASURF and beractant trials, respectively. …
About this medicine
Calfactant is an extract of natural bovine lung (pulmonary) surfactant consisting of 85% phospholipids, 8% neutral lipids, and 7% hydrophobic surfactant-associated proteins B and C (SP-B and SP-C). The molecular weight of SP-B is 8.7 kDa and the molecular weight of SP-C is 3.7 kDa.
INFASURF (calfactant) intratracheal suspension is a sterile, off-white suspension for intratracheal use. INFASURF contains calfactant at a concentration of 35 mg/mL in either a 105 mg/3 mL or 210 mg/6 mL single-dose vial. Each milliliter of INFASURF contains 35 mg of phospholipids and 0.7 mg of surface-associated proteins of which 0.26 mg is SP-B, a 79-amino acid protein, and 0.44 mg is SP-C, a 35-amino acid peptide. The amount of phospholipids is calculated from the content of phosphorous and contains 26 mg of phosphatidylcholine of which 16 mg is disaturated phosphatidylcholine. It is suspended in 0.9% Sodium Chloride Irrigation, USP. The pH is approximately 5.0 - 6.2 (target pH 5.7).
INFASURF contains no preservatives. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 315c128a-272d-4c57-bfbe-1a8b3402af08. Read the full official label on DailyMed.